Sanofi (NASDAQ:SNY) traded with a subtraction of -$0.44 to close at $48.11 on Friday, a downside of -0.91 percent. An average of 1,090,706 shares of common stock have been traded in the last five days. There was a fall of -$0.08 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 2,600,006 shares traded, while the 50-day average volume stands at 2,587,441.
SNY stock has increased by 5.84% in the last month. The company shares reached their 1-month lowest point of $44.48 on 12/06/22. With the stock rallying to its 52-week high on 04/11/22, shares of the company touched a low of $36.91 and a high of $57.79 in 52 weeks. It has reached a new high 13 times so far this year and lost -2.58% or -$1.99 in price. In spite of this, the price is down -16.75% from the 52-week high.
Sanofi (SNY) has a trailing price-to-earnings (P/E) ratio of 18.02. The stock’s beta is 0.55. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.61, the price-to-book (PB) ratio at 1.71.
The company’s most recent quarterly dividend payment was $1.7968 a share, representing a down of -5.73% from $1.9061 last year. Its latest decrease dividend $0.1093 reported on Friday April 22 2022.
The quick ratio of Sanofi for the three months ended September 29 was 0.90, and the current ratio was 1.30, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.26 and a total debt to equity ratio of 0.30 for the quarter ending September 29. Its gross profit as reported stood at $31.85 billion compared to revenue of $46.35 billion.
For the three-month period that ended September 29, Sanofi had $1.39 billion in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $13.79 billion in the quarter, while revenues were grew 77.21%. The analyst consensus anticipated Sanofi’s latest quarter earnings to come in at $1.34 per share, but it turned out to be $1.44, a 7.50% surprise. For the quarter, EBITDA amounted to $4.31 billion. At the end of the quarter ending September 29, Sanofi’s stock balance sheet showed total debt was $21.24 billion.
From a technical analysis perspective, let’s take a brief look at Sanofi (SNY) price momentum. RSI 9-day as of the close on 29 December was 58.10%, suggesting the stock is Neutral, with historical volatility in this time frame at 16.43%.
As of today, SNY’s price is $48.22 -0.17% or -$0.08 from its 5-day moving average. SNY is currently trading +4.88% higher than its 20-day SMA and -1.13% lower than its 100-day SMA. However, the stock’s current price level is +21.37% above the SMA50 and -7.30% below the SMA200.
The stochastic %K and %D were 76.53% and 74.87%, respectively, and the average true range (ATR) was 0.83. With the 14-day stochastic at 74.80% and the average true range at 0.87, the RSI (14) stands at 59.87%. The stock has reached 0.19 on the 9-day MACD Oscillator while the 14-day reading was at 0.48.
The consensus rating for Sanofi (SNY) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SNY, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 14 others rate it as a “buy”.
What is SNY’s price target for the next 12 months?
Analysts predict a range of price targets between $44.80 and $71.36, with a median target of $56.80. Taking a look at these predictions, the average price target given by analysts for Sanofi (SNY) stock is $56.24.